Alx Oncology Holdings (ALXO) EBIT (2019 - 2026)
Alx Oncology Holdings (ALXO) reported EBIT of -$19.0 million for Q1 2026, up 40.4% on a YoY basis from -$13.5 million in Q1 2025, and up 17.61% sequentially from -$23.0 million in Q4 2025.
Alx Oncology Holdings (ALXO) EBIT (2019 - 2026) Analysis & Trends
Alx Oncology Holdings (ALXO) has 8 years of EBIT data on file, last reported at -$19.0 million in Q1 2026.
- For the quarter ending Q1 2026, EBIT rose 40.4% year-over-year to -$19.0 million; the trailing twelve-month figure through Mar 2026 stood at -$91.2 million (up 33.22% YoY), and the FY2025 full-year result was -$104.0 million, up 26.99% from the prior year.
- EBIT improved to -$19.0 million in Q1 2026, from -$23.0 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$19.0 million in Q1 2026 to a low of -$53.3 million in Q3 2023.
- A 5-year average of -$33.1 million and a median of -$32.2 million in 2022 frame the typical range for EBIT.
- Across the five-year window, EBIT tumbled 107.31% in 2022 and surged 40.4% in 2026, its largest moves.
- Tracing ALXO's EBIT over 5 years: stood at -$32.2 million in 2022, then slumped by 49.05% to -$48.0 million in 2023, then surged by 36.25% to -$30.6 million in 2024, then increased by 24.8% to -$23.0 million in 2025, then increased by 17.61% to -$19.0 million in 2026.
- Business Quant data shows ALXO's EBIT at -$19.0 million in Q1 2026, -$23.0 million in Q4 2025, and -$22.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Alx Oncology Holdings | 211.24 Mn | 211.24 Mn | - | -18.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.97 Mn |
| Dec 31, 2025 | -23.02 Mn |
| Sep 30, 2025 | -22.53 Mn |
| Jun 30, 2025 | -26.65 Mn |
| Mar 31, 2025 | -31.82 Mn |
| Dec 31, 2024 | -30.61 Mn |
| Sep 30, 2024 | -32.57 Mn |
| Jun 30, 2024 | -41.53 Mn |
| Mar 31, 2024 | -37.76 Mn |
| Dec 31, 2023 | -48.02 Mn |
| Sep 30, 2023 | -53.28 Mn |
| Jun 30, 2023 | -36.78 Mn |
| Mar 31, 2023 | -32.20 Mn |
| Dec 31, 2022 | -32.22 Mn |
| Sep 30, 2022 | -36.68 Mn |
| Jun 30, 2022 | -33.79 Mn |
| Mar 31, 2022 | -24.75 Mn |
| Dec 31, 2021 | -28.47 Mn |
| Sep 30, 2021 | -24.58 Mn |
| Jun 30, 2021 | -16.30 Mn |